Table 2 Final prediction model based on multivariable logistic regression analysis for severe neutropenia in the first cycle (N=1312)

From: An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

   

Odds ratio

 
 

N

n (%)

Estimate

(95% CI)

P value

Overall P

c-index a

Regimen

      

0.693 (0.668)

FOLFIRI

840

241 (28.7)

1

—

 

0.0015

 

Irinotecan+S-1

324

53 (16.4)

0.546

(0.375, 0.794)

0.0015

  

Irinotecan monotherapy

148

29 (19.6)

0.579

(0.367, 0.914)

0.0190

  

Administered irinotecan dose (mg m−2)b

1312

323 (24.6)

—

—

—

0.0024

 

Gender

Male

818

184 (22.5)

0.686

(0.521, 0.902)

0.0070

0.0070

 

Female

494

139 (28.1)

1

—

—

  

Age (years)b

1312

323 (24.6)

—

—

—

0.0478

 

UGT1A1 genotype

Wild-type

628

119 (18.9)

1

—

—

<0.0001

 

Heterozygous

539

143 (26.5)

1.624

(1.217, 2.167)

0.0010

  

Homozygous

145

61 (42.1)

3.343

(2.191, 5.100)

<0.0001

  

ECOG PS

0

967

228 (23.6)

1

—

—

0.0811

 

1

289

80 (27.7)

1.330

(0.968, 1.828)

0.0787

  

2

56

15 (26.8)

1.749

(0.893, 3.429)

0.1034

  

Pre-treatment ANC (mm−3)b

1312

323 (24.6)

—

—

—

0.0005

 

Pre-treatment total bilirubin level, (mg dl−1)b

1312

323 (24.6)

—

—

—

0.0003

 
  1. Abbreviations: ANC=absolute neutrophil count; c-index=concordance index; 95% CI=95% confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; FOLFIRI=folinic acid, fluorouracil, and irinotecan; UGT1A1=uridine diphosphate glucuronosyltransferase 1A1.
  2. aBootstrap-corrected c-index (c-index from 10-fold cross-validation).
  3. bRestricted quadratic splines; odds ratios not applicable.
Back to article page